-
AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans
12 Nov 2025 12:00 GMT
… clinical trial evaluating TT-4, Cyncado’s selective A2B receptor antagonist, in mesothelioma … investigator-initiated clinical trial of TT-4 in mesothelioma in Australia … and implementing the Australian trial; clinical trial outcomes and regulatory approvals; …
-
Local M1 Macrophage Reprogramming with Gluconic Acid-Coated Selenium Nanoparticles
03 Dec 2025 14:31 GMT
… a marked increase in clinical trials over the past … studies into successful clinical TAMs-reprogramming therapies … administration to establish the clinical delivery method. Translational … cells against malignant pleural mesothelioma cells through the …
-
The Halpern Law Firm Proudly Sponsors the 2025 International Mesothelioma Interest Group (iMig) Conference
05 Nov 2025 16:33 GMT
… and attend the 2025 International Mesothelioma Interest Group (iMig) Conference … clinical trials, as well as discussions on prevention and early detection of mesothelioma … proudly-sponsors-the-2025-international-mesothelioma-interest-group-imig-conference- …
-
FDA Approves Faster Keytruda® Injections for Mesothelioma Patients
28 Oct 2025 15:59 GMT
… Injection Means for Mesothelioma Patients
For patients with mesothelioma, the new … treatment.
Maintains treatment effectiveness: Clinical trials show that the new injection … for multiple rounds: Many mesothelioma patients require repeated treatments. The …
-
AlphaTON (Nasdaq:ATON) and Cyncado Therapeutics: Preclinical Mesothelioma Data Show Direct A2B Tumor Activity; TT-4 Achieved >90% Tumor Growth Inhibition; First-Patient Dosing on Track for Q1 2026
27 Oct 2025 12:00 GMT
… both epithelial and non-epithelioid mesothelioma models
Quantified anti-tumor activity … to finalize clinical development plans for TT-4 in mesothelioma, with first … but not limited to: regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Path to First- Patient Dosing
25 Oct 2025 16:30 GMT
… in-human evaluation. In human mesothelioma spheroid systems, hypoxia-linked … monotherapy activity in an immunocompetent mesothelioma model, and combination treatment … but not limited to: regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
Bristol Myers Squibb data at ASH 2025 showcase potential of haematology pipeline and build momentum for next generation portfolio
02 Dec 2025 13:38 GMT
… patients with unresectable malignant pleural mesothelioma (MPM).
Opdivo (nivolumab … untreated unresectable malignant pleural mesothelioma, in combination with Yervoy … investigational protein degraders in clinical trials, leveraging three different modalities …
-
AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth
22 Oct 2025 16:00 GMT
… In an immunocompetent in vivo mesothelioma model, TT-4 monotherapy outperformed … with an initial focus on mesothelioma, advancing toward first-patient dosing … not limited to: uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty …
-
EU Agrees on Canada Joining European Defence Programme
02 Dec 2025 11:54 GMT
… Chosen as Site for New Clinical Trial in Chronic Urticaria
MANIKĀ launches … Travel Across 40 Global Cities
Mesothelioma Compensation Center and Lung Cancer … Former Power Plant Workers with Mesothelioma or Asbestos Lung Cancer to …
-
VT3989 shows promising antitumor activity in refractory mesothelioma patients
22 Oct 2025 12:39 GMT
… trial enrolled 172 patients, including 135 with refractory mesothelioma. Of the 22 mesothelioma … support the continued clinical development of VT3989 in mesothelioma, and we look … this a major unmet clinical need.
Previous trial updates
Initial data from …